CIM
CPRX

Chiron Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Chiron Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,585
Closed -$122K – 139
2022
Q4 		$122K Buy
+6,585
New +$101K 0.03% 99

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chiron Investment Management's CPRX Position: Q1 2023 in Review

Chiron Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 6,585 shares — an estimated $122K sold.

Chiron Investment Management first reported a position in CPRX in Q4 2022 and held it in 1 quarter. The position peaked at $122K in Q4 2022. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • Chiron Investment Management reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Chiron Investment Management sold 6,585 Catalyst Pharmaceutical shares in Q1 2023, an estimated $122K.
  • Chiron Investment Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 1 quarter.
  • Chiron Investment Management's Catalyst Pharmaceutical position peaked at $122K in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Chiron Investment Management's 13F filing for Q1 2023, filed 15 May 2023.